Arterial Thrombosis - Pipeline Review, H1 2017

Publisher Name :
Date: 31-Mar-2017
No. of pages: 45
Inquire Before Buying

Arterial Thrombosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H1 2017, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape.

Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arterial Thrombosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Arterial Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Arterial Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Arterial Thrombosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Arterial Thrombosis - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Arterial Thrombosis - Overview
Arterial Thrombosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arterial Thrombosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arterial Thrombosis - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bayer AG
Bristol-Myers Squibb Company
Eisai Co Ltd
Johnson & Johnson
Sanofi
Thromboserin Ltd
Arterial Thrombosis - Drug Profiles
AB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1468240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6537 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-884775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-5539 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ER-410660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PZ-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-216471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Arterial Thrombosis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Arterial Thrombosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Arterial Thrombosis - Pipeline by Astellas Pharma Inc, H1 2017
Arterial Thrombosis - Pipeline by Bayer AG, H1 2017
Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Arterial Thrombosis - Pipeline by Eisai Co Ltd, H1 2017
Arterial Thrombosis - Pipeline by Johnson & Johnson, H1 2017
Arterial Thrombosis - Pipeline by Sanofi, H1 2017
Arterial Thrombosis - Pipeline by Thromboserin Ltd, H1 2017
Arterial Thrombosis - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Arterial Thrombosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Sickle-cell Anemia Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 115
    Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. Scope of the Report: This report studies the Sickle-cell Anemia Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Sickle-cell Anemia Therapeutics market by product type and applications/end industries. The global Sickle-c......
  • Global Hemophilia Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 118
    Hemophilia is a hereditary genetic disorder which impairs body's ability to control coagulation or blood clotting. In this disease, clotting factors control bleeding from a broken vessel is deficient; therefore, coagulation does not occur. Of the two types of hemophilia, hemophilia A has higher prevalence compared to the other variant hemophilia B. . Acquired hemophilia is a rare non genetic form of hemophilia in which autoantibodies develop against the plasma coagulation factor. The development......
  • 2015-2023 World Hemophilia Treatment Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 18-Sep-2018        Price: US 2800 Onwards        Pages: 81
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • 2015-2023 World Intravenous Immunoglobulins Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 17-Sep-2018        Price: US 2800 Onwards        Pages: 82
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • Global Intravenous Immunoglobulin (IVIg) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 10-Sep-2018        Price: US 3480 Onwards        Pages: 134
    Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of Intravenous Immunoglobulin. Scope of the Report: This report focuses on the Intravenous Immunoglobulin (IVIg) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report......
  • 2018-2023 India Heparin Market Report (Status and Outlook)
    Published: 06-Sep-2018        Price: US 3360 Onwards        Pages: 83
    In 2017, the Heparin market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In India market, the top players include - Hepalink - Changshan Pharm - Qianhong Bio-pharma - Opocrin - Pfizer - Aspen Oss - King-friend Biochemical Pharmaceutical - Bioibérica - Dongcheng Biochemicals - Jiulong Biochemicals - Tiandong - Xinbai - Yino......
  • Global Fibrinogen Concentrates Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 06-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer's product are justly used in local region or countries.......
  • 2018-2023 Philippines Heparin Market Report (Status and Outlook)
    Published: 06-Sep-2018        Price: US 3360 Onwards        Pages: 83
    In 2017, the Heparin market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In Philippines market, the top players include - Hepalink - Changshan Pharm - Qianhong Bio-pharma - Opocrin - Pfizer - Aspen Oss - King-friend Biochemical Pharmaceutical - Bioibérica - Dongcheng Biochemicals - Jiulong Biochemicals - Tiandong - Xinbai......
  • 2018-2023 UK Heparin Market Report (Status and Outlook)
    Published: 06-Sep-2018        Price: US 3360 Onwards        Pages: 83
    In 2017, the Heparin market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the top players include - Hepalink - Changshan Pharm - Qianhong Bio-pharma - Opocrin - Pfizer - Aspen Oss - King-friend Biochemical Pharmaceutical - Bioibérica - Dongcheng Biochemicals - Jiulong Biochemicals - Tiandong - Xinbai - Yino Pharm......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs